Replies to post #227144 on Biotech Values

[DewDiligence]

AXSM—I think the management has the data on hand and will be PR'd soon. Why else they would have KOL/Investor's meeting?

I don’t buy that. Many biotech companies have had KOL webcasts for investors and gone on to report mixed or failed clinical data.

[bellweather1]

Regarding the AXSM Momentum(Migraine)Trial: I suspect that, at the least, compliance issues and other trial unknowns have been minimized since the entire trial is being run thru a single company-managed trial site in Miami, Florida.

In addition, considering that this is a triptan study, I think we can assume that none of it's participants have a Cardiovascular Hx. Therefore, since all have had an inadequate Tx response Hx, I think we can also assume that the overwhelming majority(80%+) have failed on triptans, and are likely(at least to some significant degree)to do so here.

As a result, the superior speed & efficacy of the MoSEIC meloxicam component of AXS-07 becomes a critical curve dividing factor, but when combined with the synergistic pharmokinetics of both AXS-07 components, it's a lot easier to imagine how AXS-07's performance in this pt population will significantly outpace standard Riza., standard Meloxicam & placebo at both intervals(2 & 24 hours).

Therefore, although there is always trial risk, the bar, imo, isn't nearly as high as many appear to expect, and the chances for success across the board are very good:-)